#United Kingdom #Biocomposites #Keele #STIMULAN #BIG D-FOOT

Introduction to the BIG D-FOOT Study

The BIG D-FOOT study is a significant research effort aiming to address one of the most challenging conditions in modern medicine—diabetic foot osteomyelitis (DFO). Conducted by Biocomposites, a leading international medical devices company specialized in infection management, this research focuses on the local delivery of antibiotics via STIMULAN®, showcasing a promising approach to reducing post-surgical infections.

Study Highlights

This double-blinded, randomized controlled trial has provided compelling results, highlighting the superiority of antibiotic-loaded STIMULAN® over a placebo. Key findings from this study include:

• - Reduction in Infective Complications: The use of STIMULAN® significantly lowers the risks of post-surgical complications, including the recurrence of DFO.
• - Early Termination Due to Efficacy: The study was terminated early owing to its robust findings, clearly demonstrating the effectiveness of STIMULAN® in managing this complex condition.
• - Achievement of Full Healing: A patient initially in the placebo group, later receiving STIMULAN® combined with antibiotics, achieved complete healing within two months, underscoring the treatment's potential.
• - Cost Comparison: Economic analysis revealed that the approach using STIMULAN® is comparably sustainable to traditional methods in terms of cost.

Biocomposites at EBJIS 2025

Biocomposites will be a Platinum Sponsor of the 43rd Annual Meeting of the European Bone Joint Infection Society (EBJIS), taking place from September 11 to 13, 2025, at the Bologna Congress Centre in Italy. The company will present its innovative products, including STIMULAN®, the first absorbable calcium matrix approved for use with antibiotics in bone and soft tissue, and SYNICEM Spacers, pre-formed antibiotic-loaded devices supporting infection treatment.

The Biocomposites symposium titled "From diabetic foot osteomyelitis to peri-prosthetic joint infection what are the most appropriate treatment strategies?" will further delve into the study’s insights and the best practices for managing complex infections. Esteemed clinicians including Dr. Massimiliano De Paolis and Professor Pierluigi Viale will moderate this session, featuring presentations from leading experts such as Dr. Matteo Monami, the lead author of the BIG D-FOOT study.

Expert Discussions

The symposium is designed to be interactive and informative, addressing the most pressing questions on treatment strategies for complex infections. Discussions will involve topics such as:

• - Results from the BIG D-FOOT study and its implications for DFO treatment.
• - New recommendations regarding local antibiotic administration and insights following the 2025 Consensus Meeting.
• - The evolving role of local antimicrobials and bacteriophages in treating diabetic foot infections.

Conclusion

Michael Harris, CEO of Biocomposites, expresses enthusiasm for participating in EBJIS 2025, emphasizing the importance of STIMULAN® in managing critical infections. He notes that the results from the BIG D-FOOT study contribute significantly to validating this treatment method both clinically and economically, providing a new pathway for surgeons tackling DFO challenges.

Biocomposites continues to lead the way in developing innovative solutions aimed at not only enhancing surgical outcomes but also improving the standard of care for patients grappling with complex infections.

For more information about Biocomposites and its products, visit biocomposites.com.

Additional Details for the Symposium

Date & Time: September 12, 2025, from 12:50 to 13:50 CEST
Location: Room Sala Italia, Bologna Congress Centre

This symposium stands out as a vital event for healthcare professionals interested in the latest advances pertaining to infection management in surgical practices, providing a platform for knowledge sharing and collaboration.